Blarcamesine hydrochloride (AVex-73 hydrochloride) is a Sigma-1 Receptor agonist (IC50: 860 nM).

σ1:860 nM

The pretreatment of Blarcamesine(1/3 mg/kg) dose-dependently reduces the scopolamine-induced alternation deficit. The pretreatment with Blarcamesine(>0.3 mg/kg) dose-dependently and significantly attenuates the impairments of step-through latency[1]. The Blarcamesine(1mg/kg) dose-dependently blocks the recognition memory deficit. One day after injections, the significant Aβ25-35-induced decrease in Akt phosphorylation is significantly attenuated by Blarcamesine(0.1/1mg/kg). Seven days after injections, Blarcamesineattenuates the decrease in Ser9 phosphorylation induced by the peptide (0.3/1mg/kg)[2].

Drugs (including Anavex 2-73) are solubilized in physiological saline at the concentration of 5?mg/mL.Male mice aged 7-9 weeks and weighing 32±2?g are used. Drugs (including Anavex 2-73) are brought up to each dose by dilution and injected in a volume of 100?μL/20?g body weight. Animals are used between days 1 and 9 after i.c.v. injections for behavioral testing or killed before biochemical measures.